1523. The Diagnostic Role of suPAR for Diabetic Foot Infections
Session: Poster Abstract Session: Clinical Infectious Diseases: Diabetic Foot Infections
Saturday, October 10, 2015
Room: Poster Hall
  • Abstract-1523.pdf (135.2 kB)
  • Background: Among diabetic patients, 20% of hospital admissions are due to diabetic foot infections (DFIs). DFI is also the most important cause of lower extremity amputations. Increased level of soluble urokinase-type plasminogen activator receptor (suPAR) is accepted as markers of activation of immune and inflammatory systems. In this study we aimed to investigate whether the level of serum suPAR is correlated with the severity of diabetic foot infection or not and whether it has superiority to conventional infection markers such as white blood cell count (WBC), erythrocyte sedimentation rate (ESH), c-reactive protein (CRP), procalcitonin (PCT) or not.

    Methods: Patients those are diagnosed as diabetic foot ulcer and DFI in Izmir Katip Celebi University Ataturk Training Research Hospital, between April 2014 and April 2015 were enrolled in the study.  Healthy individuals and diabetic patients without any infection focus were defined as control group. DFI diagnosis and severity of infection were based on Infectious Diseases Society of America (IDSA) guidelines. Participants were classified in 4 groups. Conventional infection markers (WBC, ESH, CRP, PCT) were studied for each participant. ELISA method was used for suPAR detection in peripheral blood.

    Results: Totally 159 patients; 81 (%50.9) male and 78 (%49.05) female, were enrolled into study. All of infection markers including suPAR were significantly higher in Group 4 compared to others (p=0.000)(Table 1). A significant correlation was also found in severity of infection (Table 2). suPAR and ESH  levels were significantly higher in patients with osteomyelitis (p=0.041; p=0.001).

    Conclusion: Results of our study suggest that suPAR is an alternative infection marker in DFIs. High levels of suPAR have correlation with severity of infection. And it can be used as an alternative marker to ESH in osteomyelitis.

    Sevinc Aslan, Dr1, Tuna Demirdal, Dr1, Atakan Nemli, Dr1, Huriye Erbak, Dr2, Cem Aslan, Dr3, Ilknur Vardar, Dr1 and Recep Sutcu, Dr2, (1)Infectious Diseases, Izmir Katip Celebi University, Ataturk Training and Research Hospital, Izmir, Turkey, (2)Medical Biochemistry, Izmir Katip Celebi University, Ataturk Training and Research Hospital, Izmir, Turkey, (3)Plastic Surgery, Izmir Katip Celebi University, Ataturk Training and Research Hospital, Izmir, Turkey


    S. Aslan, None

    T. Demirdal, None

    A. Nemli, None

    H. Erbak, None

    C. Aslan, None

    I. Vardar, None

    R. Sutcu, None

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 7th with the exception of research findings presented at the IDWeek press conferences.